Join the club for FREE to access the whole archive and other member benefits.

CohBar's lead candidate may initiate clinical trials in 2022

16-Mar-2021

Key points from article :

CohBar announced the selection of CB5138-3 as its lead candidate for advancement into Investigational New Drug-enabling activities.

Discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs.

CB5138-3 is a CB5138 Analog, with potential for treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases.

“Positive preclinical data support CB5138-3 as a potential antifibrotic and anti-inflammatory therapeutic for IPF,” - Steven Engle, CohBar’s Chief Executive Officer.

Demonstrated positive effects including reduction of fibrosis, inflammation and collagen deposition.

Enhanced effects in combination with the standard of care nintedanib.

IND-enabling activities for CB5138-3 with the goal of initiating clinical studies in 2022.

CB4211 is in the Phase 1b stage for NASH and obesity.

Four preclinical programmes for fibrotic diseases, COVID-19 associated ARDS, cancer immunotherapy, CXCR4-related cancer and orphan diseases.

Mitochondrial-based therapy enters IND to tackle IPF and other fibrotic diseases

Mentioned in this article:

Company

Company focused on the research and development of mitochondria based therapeutics.

Company Representative

Chief Executive Officer & Director, CohBar